Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Hoffmann-La Roche
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A Study of Alectinib versus Pemetrexed or Docetaxel in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer
To evaluate and compare between treatment groups the efficacy of alectinib versus chemotherapy in patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) wh...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
GO27819 : Essai de phase 2 randomisé évaluant l’efficacité et la tolérance de l’onartuzumab (MetMAb) en association avec le bévacizumab ou en monothérapie, chez des patients ayant un glioblastome récurrent. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est d’évaluer l’efficacité et la tolérance de l’onartuzumab (MetMAb) en association avec le bévacizumab ou en monothérapie, chez des patients ayant un glioblastome récurrent. ...
Country
France
organs
Cerveau
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A single arm Phase IV study to assess efficacy and safety of bevacizumab in combination with irinotecan and infusional 5-fluorouracil/folinic acid regimens as first line treatment for patients with metastatic colorectal cancer
To determine the efficacy of bevacizumab in combination with irinotecan and infusional 5-fluorouracil plus folinic acid based regimens as compared with historical controls, based on progression free s...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
HOFFMANN LA ROCHE BP22350 : Essai de phase 1 comparant la tolérance d’un anticorps anti-EGFR (RO5083945) à celle du cétuximab chez des patients ayant un carcinome à cellules squameuses de la tête et du cou. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
An exploratory, open label multicenter study to investigate pharmacodynamic of RO5083945, a human monoclonal antibody antagonist of epidermal growth factor receptor (EGFR), compared to cetuximab in pa...
Country
France
organs
Tête et cou
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A randomized phase III clinical study of bevacizumab plus capecitabine vs. bevacizumab alone as maintenance therapy in patients with HER2-negative metastatic breast cancer that has not progressed during first-line docetaxel plus bevacizumab therapy
To evaluate whether maintenance therapy with bevacizumab plus capecitabine, compared to bevacizumab alone, can further increase Progression-Free Survival (PFS) in patients showing objective response o...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man
Between 18 years
and 99 years
Hoffmann-La Roche
Update Il y a 4 ans
Hoffmann-La Roche NO21895 : Essai de phase 1-2 évaluant la tolérance, la pharmacocinétique et l’efficacité d’un traitement par RO5126766 (inhibiteur MEK et Raf), chez des patients ayant une tumeur solide. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions]
L’objectif de cet essai est de déterminer la dose la plus adaptée de RO5126766, à administrer chez des patients ayant un tumeur solide avancé, puis d’évaluer l’efficacité du traitement, chez des patie...
Country
France
organs
Tumeurs solides
Specialty
Thérapies Ciblées
Essai clos aux inclusions
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ATEZOLIZUMAB (ANTI−PD-L1 ANTIBODY) COMPARED WITH BEST SUPPORTIVE CARE FOLLOWING LUNG CANCER RESECTION AND CHEMOTHERAPY FOR EARLY STAGE LUNG CANCER
To evaluate the efficacy of 16 cycles of atezolizumab treatment compared with best supportive care as measured by disease-free survival (DFS) as assessed by the investigator.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A double blind, randomized, placebo controlled, multi-center trial of oseltamivir for the seasonal prophylaxis of influenza in immunocompromised patients
The primary objective of the study is to evaluate prospectively the efficacy of oseltamivir in the seasonal prophylaxis of influenza as measured by the relative incidence of laboratory confirmed clini...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A randomized, multicenter, Phase II study of the efficacy and safety of trastuzumab-MCC-DM1 vs. trastuzumab (Herceptin®) and docetaxel (Taxotere®) in patients with metastatic HER2-positive breast cancer who have not received prior chemotherapy for metastatic disease
The primary objectives for this study are as follows: • To explore the efficacy of T-DM1 compared with the combination of trastuzumab and docetaxel in patients with HER2-positive, unresectable, locall...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
F. Hoffmann-La Roche Ltd
Update Il y a 4 ans
A multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety and tolerability of taspoglutide (RO5073031) compared to placebo in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
The primary objective is to determine the efficacy of taspoglutide based on glycemic control (as assessed by HbA1c) compared with placebo in drug-naïve patients with type 2 diabetes after 24 weeks of ...
Country
None
organs
None
Specialty
None
unknown
More information
Previous
4
5
6
7
8
9
10
11
12
13
Next